NOVELTY - Solid medicinal composition comprises (in wt.%) 2.5-20 mg of flurbiprofen or its salt or ester (0.25-1), and excipients comprising lubricant (1-5), sweetener (0.5-5), diluent (84-98) and binder (0.25-5). The lubricant is e.g. glycerol dibehenate, starch, sodium lauryl sulfate, talc, glycerides and/or sodium benzoate. The sweetener is e.g. acesulfame potassium, sorbitol, mannitol, isomalt, cyclamate, and/or sucralose. The diluent is e.g. calcium phosphate, starch, kaolin, glucans and/or xyloglucan. The binder is e.g. polyvinyl pyrrolidone, polyethylene glycol and/or propylene glycol.    USE - The solid medicinal composition is useful for treating inflammations of the oral cavity (claimed), fever and/or joint pain.    ADVANTAGE - The flurbiprofen is released in mouth in a period of greater than 15 minutes, with acceptable palatability. The solid medicinal composition: does not cause unpleasant burning sensation or irritation; exhibits good tolerability, stability and bioavailability; can be obtained without sugars, such as glucose, thus the composition can be used for diabetic patients; and can be obtained in a single step, thus avoiding problems of degradation of active ingredient and excipients. The bioavailability of the solid composition comprising flurbiprofen was tested in 26 healthy volunteers of 18-55 years by administering the composition for five consecutive days. The result showed that the composition (comprising 8.75 mg of flurbiprofen, 20 mg of glycerol dibehenate, 8 mg of acesulfame potassium, 913.25 mg of mannitol, 5 mg of copovidone and 45 mg of balsamic mint flavor) exhibited a maximal flurbiprofen plasma concentration observed in plasma (Cmax) of 1.912 plus minus 1.47 mu g/ml on the sixth day after the last administration.    DETAILED DESCRIPTION - Solid medicinal composition comprises (in wt.%) 2.5-20 mg of flurbiprofen or its salt or ester (0.25-1), and excipients comprising lubricant (1-5), sweetener (0.5-5), diluent (84-98) and binder (0.25-5). The lubricant is glycerol dibehenate, stearates of calcium or magnesium, sodium stearyl fumarate, hydrogenated oils, vegetable oils, palmitic acid, alcohol, starch, mineral oils, polyethylene glycols, sodium lauryl sulfate, talc, glycerides and/or sodium benzoate. The sweetener is acesulfame potassium, sorbitol, mannitol, isomalt, maltitol, lactitol, xylitol, aspartame, cyclamate, cyclamate salts, lactose, saccharin, saccharin salts and/or sucralose. The diluent is calcium phosphate, starch, kaolin, calcium sulfate dihydrate, calcium carbonate, lactose, sucrose, mannitol, polysaccharides, glucans and/or xyloglucan. The binder is polyvinyl pyrrolidone, starches, natural or synthetic gums and gelatin, polyethylene glycol and/or propylene glycol. An INDEPENDENT CLAIM is also included for producing the solid pharmaceutical composition in form of lozenges, comprising sieving the solid components, adding the solid components in a V-blender under stirring conditions, dividing the obtained homogenous mixture in dosage units comprising 2.5-20 mg, preferably 5-15 mg of flurbiprofen, and obtaining the lozenges by direct compression.